Last reviewed · How we verify

Blastic plasmacytoid dendritic cell neoplasm — Treatment Landscape & Competitive Intelligence

Blastic plasmacytoid dendritic cell neoplasm (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Blastic plasmacytoid dendritic cell neoplasm, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Molecule 129 TAGRAXOFUSP Stemline Therapeeutics Inc CD123 Interaction [EPC] Elongation factor 2 2018-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Stemline Therapeeutics Inc · 1 drug in Blastic plasmacytoid dendritic cell neoplasm

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Blastic plasmacytoid dendritic cell neoplasm:

Cite this brief

Drug Landscape (2026). Blastic plasmacytoid dendritic cell neoplasm — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/blastic-plasmacytoid-dendritic-cell-neoplasm. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing